• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults.非达霉素（Dificid），一种用于治疗成人艰难梭菌相关性腹泻的新型口服大环内酯类抗菌药物。
P T. 2012 May;37(5):278-81.
2
A case report of successful management of clostridium difficile colitis with antegrade Fidaxomicin through a mucous fistula obviating the need for subtotal colectomy.经黏液瘘口顺行使用非达霉素成功治疗艰难梭菌结肠炎且无需行结肠次全切除术的病例报告
Int J Surg Case Rep. 2018;42:79-81. doi: 10.1016/j.ijscr.2017.11.042. Epub 2017 Nov 27.
3
Stability and recovery of DIFICID(®) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube.200毫克达福普明（DIFICID®）（非达霉素）碾碎片剂在三种给药载体中的稳定性及恢复情况，以及通过鼻胃管给予水分散体。
Drugs R D. 2014 Dec;14(4):309-14. doi: 10.1007/s40268-014-0067-3.
4
Role of fidaxomicin for the treatment of Clostridium difficile infection.非达霉素在艰难梭菌感染治疗中的作用。
J Pharm Pract. 2013 Oct;26(5):491-7. doi: 10.1177/0897190013499526.
5
[Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir), a therapeutic agent for Clostridioides (Clostridium) difficile infection].非达霉素（Dafclir）治疗艰难梭菌感染的抗菌谱及临床证据
Nihon Yakurigaku Zasshi. 2019;154(4):217-229. doi: 10.1254/fpj.154.217.
6
Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.比较 fidaxomicin 与口服万古霉素治疗艰难梭菌感染的安全性分析。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S110-5. doi: 10.1093/cid/cis390.
7
Fidaxomicin for the treatment of Clostridium difficile infections. fidaxomicin 治疗艰难梭菌感染。
Ann Pharmacother. 2012 Feb;46(2):219-28. doi: 10.1345/aph.1Q481. Epub 2012 Feb 7.
8
Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.比较 fidaxomicin 与口服万古霉素治疗成人艰难梭菌相关性腹泻的疗效和安全性：来自 OPT-80-003 和 OPT-80-004 研究的数据。
Future Microbiol. 2012 Jun;7(6):677-83. doi: 10.2217/fmb.12.44.
9
Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.非达霉素：一种用于治疗艰难梭菌感染的大环内酯类抗生素。
Pharmacotherapy. 2011 Sep;31(9):877-86. doi: 10.1592/phco.31.9.877.
10
Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.利福昔明治疗艰难梭菌感染的研究进展：一种窄谱抗生素。
Ann N Y Acad Sci. 2013 Jul;1291:33-41. doi: 10.1111/nyas.12135. Epub 2013 May 14.

引用本文的文献

1
Exploring novel microbial metabolites and drugs for inhibiting .探索新型微生物代谢产物及抑制 的药物。
mSphere. 2024 Jul 30;9(7):e0027324. doi: 10.1128/msphere.00273-24. Epub 2024 Jun 28.
2
Current and Ongoing Developments in Targeting Infection and Recurrence.针对感染和复发的当前及正在进行的进展。
Microorganisms. 2024 Jun 15;12(6):1206. doi: 10.3390/microorganisms12061206.
3
Validation of clinical risk tools for recurrent infection.复发性感染临床风险评估工具的验证
Infect Control Hosp Epidemiol. 2024 May 9;45(9):1-9. doi: 10.1017/ice.2024.75.
4
Novel Biomarkers, Including PCR Cycle Threshold, for Predicting Recurrent Clostridioides difficile Infection.新型生物标志物，包括 PCR 循环阈值，可预测复发性艰难梭菌感染。
Infect Immun. 2023 Apr 18;91(4):e0009223. doi: 10.1128/iai.00092-23. Epub 2023 Mar 28.
5
Pathogenicity and virulence of . 的致病性和毒力。
Virulence. 2023 Dec;14(1):2150452. doi: 10.1080/21505594.2022.2150452.
6
In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.金诺芬在仓鼠艰难梭菌感染模型中的体内疗效。
Sci Rep. 2021 Mar 29;11(1):7093. doi: 10.1038/s41598-021-86595-3.
7
Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility.亚抑菌浓度甲硝唑对不同敏感性艰难梭菌菌株蛋白质组的影响。
PLoS One. 2020 Nov 9;15(11):e0241903. doi: 10.1371/journal.pone.0241903. eCollection 2020.
8
Natural products as inspiration for the development of bacterial antibiofilm agents.天然产物可作为开发细菌抗生物膜剂的灵感来源。
Nat Prod Rep. 2020 Nov 1;37(11):1454-1477. doi: 10.1039/d0np00022a. Epub 2020 Jul 1.
9
Screening for potent and selective anticlostridial leads among FDA-approved drugs.筛选 FDA 批准药物中的有效且选择性的抗梭菌先导化合物。
J Antibiot (Tokyo). 2020 Jun;73(6):392-409. doi: 10.1038/s41429-020-0288-3. Epub 2020 Mar 4.
10
Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.2013 - 2015年美国10个地理位置成年患者艰难梭菌感染的治疗及治疗指南依从性情况
J Gen Intern Med. 2020 Feb;35(2):412-419. doi: 10.1007/s11606-019-05386-9. Epub 2019 Nov 25.

本文引用的文献

1
Comparative effectiveness of Clostridium difficile treatments: a systematic review.艰难梭菌治疗方法的疗效比较：系统评价。
Ann Intern Med. 2011 Dec 20;155(12):839-47. doi: 10.7326/0003-4819-155-12-201112200-00007.
2
Fidaxomicin approved for C. difficile infections.非达霉素获批用于艰难梭菌感染。
Am J Health Syst Pharm. 2011 Jul 15;68(14):1276. doi: 10.2146/news110046.
3
Fidaxomicin versus vancomycin for Clostridium difficile infection. fidaxomicin 与万古霉素治疗艰难梭菌感染。
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
4
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).艰难梭菌感染临床实践指南：美国医疗保健流行病学学会（SHEA）和美国传染病学会（IDSA）2010 年更新版。
Infect Control Hosp Epidemiol. 2010 May;31(5):431-55. doi: 10.1086/651706.
5
Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.1999 - 2004年美国艰难梭菌相关死亡率的上升
Emerg Infect Dis. 2007 Sep;13(9):1417-9. doi: 10.3201/eid1309.061116.
6
Clostridium difficile--associated diarrhea.艰难梭菌相关性腹泻
Am Fam Physician. 2005 Mar 1;71(5):921-8.
7
In vitro activity of OPT-80 against Clostridium difficile.OPT-80对艰难梭菌的体外活性。
Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. doi: 10.1128/AAC.48.6.2280-2282.2004.
8
Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.暴发性艰难梭菌感染：一种未得到充分认识且导致死亡和并发症不断增加的病因。
Ann Surg. 2002 Mar;235(3):363-72. doi: 10.1097/00000658-200203000-00008.
9
Clinical practice. Antibiotic-associated diarrhea.临床实践。抗生素相关性腹泻。
N Engl J Med. 2002 Jan 31;346(5):334-9. doi: 10.1056/NEJMcp011603.
10
Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.艰难梭菌所致医院内腹泻的医疗费用及死亡率
Clin Infect Dis. 2002 Feb 1;34(3):346-53. doi: 10.1086/338260. Epub 2001 Dec 17.

Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults.

作者信息

Cruz Martin Paspe

出版信息

P T. 2012 May;37(5):278-81.

PMID:22876085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3411227/
Abstract
摘要